Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

Shiqi Wang, Saowanee Wannasarit, Patricia Figueiredo, Giuseppina Molinaro, Yaping Ding, Alexandra Correia, Luca Casettari, Ruedeekorn Wiwattanapatapee, Jouni Hirvonen, Dongfei Liu, Wei Li, Hélder A. Santos

Research output: Contribution to journalArticleScientificpeer-review


In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.
Original languageEnglish
Article number2000058
JournalAdvanced Therapeutics
Issue number1
Number of pages11
Publication statusPublished - Jan 2021
MoE publication typeA1 Journal article-refereed

Fields of Science

  • drug delivery
  • endosomal escape
  • macrophage phenotypes
  • microfluidics
  • polydopamine
  • 317 Pharmacy
  • 221 Nano-technology
  • 318 Medical biotechnology

Cite this